Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Grifols turns human blood plasma into medicines for people with immune disorders, bleeding problems, and other serious conditions, and also sells diagnostic testing equipment.
Grifols is a Spanish healthcare company that makes medicines from human blood plasma. Plasma is the yellowish liquid part of blood, and it contains proteins that the body uses to fight infections and stop bleeding. Grifols collects plasma from donors at hundreds of centers, mostly in the United States, then ships it to factories where it is separated and purified into treatments for people with rare immune deficiencies, liver disease, and bleeding disorders.
The plasma business is the engine. Plasma-derived medicines take a long time to make — roughly seven to twelve months from donation to finished vial — and the factories are expensive and heavily regulated. That makes the business hard to enter and gives the biggest players real power. Grifols is one of a small group of global plasma companies, competing with CSL and Takeda Pharmaceutical among others. Grifols also sells diagnostic testing equipment, mainly blood-typing and screening tools for hospitals and blood banks, and it holds a stake in a business that makes hospital pharmacy software. The company has been through a messy stretch. It carries a heavy debt load built up from years of acquisitions, and in 2024 short-seller Gotham City Research published reports questioning its accounting and its reported profits, sending the shares sharply lower. Grifols denied the claims, but the episode damaged investor trust and drew attention to its leverage. Management has since focused on cutting costs, selling non-core assets, and bringing down debt, while the core plasma business has been working through a period of tight plasma supply and thin margins.
The simple version: Grifols sells a product made from something people give away for free, and it turns that raw material into high-priced medicine through slow, capital-hungry factories. That is a durable advantage when the factories run well and the balance sheet is calm. It is a dangerous business when debt is high and investors start doubting the numbers.
Saved answer · last researched 15 Nov 2026